|
Sep 24
|
Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options
|
|
Jun 20
|
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy
|
|
Jun 19
|
Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically
|
|
Jun 18
|
Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically
|
|
Jan 15
|
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
|
|
Dec 4
|
Theralase makes positive progress on Phase II study on bladder cancer; targets breakthrough designation with FDA
|
|
Nov 29
|
Theralase Release's 3Q2023 Interim Financial Statements
|
|
Nov 29
|
Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement
|
|
Oct 23
|
Theralase(R) Announces Brokered LIFE Financing
|
|
Oct 23
|
Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study
|
|
Sep 7
|
Theralase(R) Closes Private Placement Equity Financing
|